AR090544A1 - Metodo para tratar selectivamente a un sujeto que tenga cancer - Google Patents
Metodo para tratar selectivamente a un sujeto que tenga cancerInfo
- Publication number
- AR090544A1 AR090544A1 ARP130101029A AR090544A1 AR 090544 A1 AR090544 A1 AR 090544A1 AR P130101029 A ARP130101029 A AR P130101029A AR 090544 A1 AR090544 A1 AR 090544A1
- Authority
- AR
- Argentina
- Prior art keywords
- subject
- cancer
- treating
- selectly
- pi3k
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
- C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/156—Polymorphic or mutational markers
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Analytical Chemistry (AREA)
- Zoology (AREA)
- Pathology (AREA)
- Genetics & Genomics (AREA)
- Immunology (AREA)
- Wood Science & Technology (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Oncology (AREA)
- Biochemistry (AREA)
- Epidemiology (AREA)
- General Engineering & Computer Science (AREA)
- Physics & Mathematics (AREA)
- Biophysics (AREA)
- Biotechnology (AREA)
- Microbiology (AREA)
- Molecular Biology (AREA)
- Hospice & Palliative Care (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Investigating Or Analysing Biological Materials (AREA)
Abstract
Regímenes de tratamiento de cáncer selectivos basados en ensayos para determinar la presencia o ausencia de una mutación en un ácido nucleico que codifica glutamina en la posición 859 de la subunidad catalítica p110a de PI3K. Reivindicación 1: Un método para tratar selectivamente a un sujeto que tenga cáncer, el cual comprende administrar selectivamente una cantidad terapéuticamente efectiva de la 1-({4-metil-5-[2-(2,2,2-trifluoro-1,1-dimetil-etil)-piridin-4-il]-tiazol-2-il}-amida) de 2-amida del ácido (S)-pirrolidin-1,2-dicarboxílico, o de una sal farmacéuticamente aceptable de la misma, al sujeto, con base en que el sujeto tenga una glutamina en la posición 859 de la subunidad catalítica p110a de PI3K.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261617284P | 2012-03-29 | 2012-03-29 | |
| US201361767848P | 2013-02-22 | 2013-02-22 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR090544A1 true AR090544A1 (es) | 2014-11-19 |
Family
ID=48083130
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP130101029 AR090544A1 (es) | 2012-03-29 | 2013-03-27 | Metodo para tratar selectivamente a un sujeto que tenga cancer |
Country Status (25)
| Country | Link |
|---|---|
| US (1) | US9795596B2 (es) |
| EP (1) | EP2830621B1 (es) |
| JP (1) | JP6224067B2 (es) |
| KR (1) | KR20140138771A (es) |
| CN (1) | CN104271136A (es) |
| AR (1) | AR090544A1 (es) |
| AU (1) | AU2013241752B2 (es) |
| BR (1) | BR112014023530A2 (es) |
| CA (1) | CA2866127A1 (es) |
| CL (1) | CL2014002576A1 (es) |
| CO (1) | CO7091176A2 (es) |
| EA (1) | EA028984B1 (es) |
| EC (1) | ECSP14025016A (es) |
| ES (1) | ES2845560T3 (es) |
| GT (1) | GT201400206A (es) |
| HK (1) | HK1200723A1 (es) |
| IL (1) | IL234658B (es) |
| IN (1) | IN2014DN08970A (es) |
| MX (1) | MX2014011682A (es) |
| NZ (1) | NZ628596A (es) |
| PH (1) | PH12014502168A1 (es) |
| SG (2) | SG10201608001RA (es) |
| TW (1) | TW201345525A (es) |
| WO (1) | WO2013144249A1 (es) |
| ZA (1) | ZA201405938B (es) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2968349A2 (en) * | 2013-03-15 | 2016-01-20 | Novartis AG | Biomarkers of tumor pharmacodynamic response |
| EP3140427B1 (en) * | 2014-05-09 | 2020-10-14 | Memorial Sloan Kettering Cancer Center | Biomarkers for response to pi3k inhibitors |
| AU2015326392B2 (en) * | 2014-10-03 | 2018-10-04 | Novartis Ag | Pharmaceutical compositions comprising alpelisib |
| AU2016362683B2 (en) * | 2015-12-03 | 2019-11-07 | Novartis Ag | Treatment of cancer with a PI3K inhibitor in a patient preselected for having a PIK3CA mutation in the ctDNA |
| WO2019199860A1 (en) * | 2018-04-09 | 2019-10-17 | The Research Foundation For The State University Of New York | Genetically modified t-cells and pi3k/akt inhibitors for cancer treatment |
Family Cites Families (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4965188A (en) | 1986-08-22 | 1990-10-23 | Cetus Corporation | Process for amplifying, detecting, and/or cloning nucleic acid sequences using a thermostable enzyme |
| DE68908054T2 (de) | 1988-01-21 | 1994-03-10 | Genentech Inc | Verstärkung und nachweis von nukleinsäuresequenzen. |
| CA1340807C (en) | 1988-02-24 | 1999-11-02 | Lawrence T. Malek | Nucleic acid amplification process |
| US5130238A (en) | 1988-06-24 | 1992-07-14 | Cangene Corporation | Enhanced nucleic acid amplification process |
| EP0425563B1 (en) | 1988-07-20 | 1996-05-15 | David Segev | Process for amplifying and detecting nucleic acid sequences |
| US5169766A (en) | 1991-06-14 | 1992-12-08 | Life Technologies, Inc. | Amplification of nucleic acid molecules |
| US5846717A (en) | 1996-01-24 | 1998-12-08 | Third Wave Technologies, Inc. | Detection of nucleic acid sequences by invader-directed cleavage |
| US5605798A (en) | 1993-01-07 | 1997-02-25 | Sequenom, Inc. | DNA diagnostic based on mass spectrometry |
| GB2453173A (en) | 2007-09-28 | 2009-04-01 | Dxs Ltd | Polynucleotide primers |
| WO2010005558A2 (en) | 2008-07-07 | 2010-01-14 | Xcovery, Inc. | Pi3k isoform selective inhibitors |
| UA104147C2 (uk) | 2008-09-10 | 2014-01-10 | Новартис Аг | Похідна піролідиндикарбонової кислоти та її застосування у лікуванні проліферативних захворювань |
| CN101445832B (zh) | 2008-12-23 | 2011-09-14 | 广州益善生物技术有限公司 | Pik3ca基因突变的检测探针、液相芯片及其检测方法 |
| AR082418A1 (es) * | 2010-08-02 | 2012-12-05 | Novartis Ag | Formas cristalinas de 1-(4-metil-5-[2-(2,2,2-trifluoro-1,1-dimetil-etil)-piridin-4-il]-tiazol-2-il)-amida de 2-amida del acido (s)-pirrolidin-1,2-dicarboxilico |
-
2013
- 2013-03-27 MX MX2014011682A patent/MX2014011682A/es unknown
- 2013-03-27 IN IN8970DEN2014 patent/IN2014DN08970A/en unknown
- 2013-03-27 AU AU2013241752A patent/AU2013241752B2/en not_active Ceased
- 2013-03-27 WO PCT/EP2013/056600 patent/WO2013144249A1/en active Application Filing
- 2013-03-27 SG SG10201608001RA patent/SG10201608001RA/en unknown
- 2013-03-27 EP EP13715169.2A patent/EP2830621B1/en active Active
- 2013-03-27 NZ NZ628596A patent/NZ628596A/en not_active IP Right Cessation
- 2013-03-27 CA CA 2866127 patent/CA2866127A1/en not_active Abandoned
- 2013-03-27 AR ARP130101029 patent/AR090544A1/es unknown
- 2013-03-27 BR BR112014023530A patent/BR112014023530A2/pt not_active IP Right Cessation
- 2013-03-27 SG SG11201405169SA patent/SG11201405169SA/en unknown
- 2013-03-27 US US14/387,653 patent/US9795596B2/en active Active
- 2013-03-27 CN CN201380017393.0A patent/CN104271136A/zh active Pending
- 2013-03-27 JP JP2015502341A patent/JP6224067B2/ja active Active
- 2013-03-27 KR KR1020147026735A patent/KR20140138771A/ko not_active Application Discontinuation
- 2013-03-27 ES ES13715169T patent/ES2845560T3/es active Active
- 2013-03-27 EA EA201491787A patent/EA028984B1/ru not_active IP Right Cessation
- 2013-03-28 TW TW102111262A patent/TW201345525A/zh unknown
-
2014
- 2014-08-13 ZA ZA2014/05938A patent/ZA201405938B/en unknown
- 2014-09-15 IL IL234658A patent/IL234658B/en not_active IP Right Cessation
- 2014-09-26 CL CL2014002576A patent/CL2014002576A1/es unknown
- 2014-09-26 PH PH12014502168A patent/PH12014502168A1/en unknown
- 2014-09-29 GT GT201400206A patent/GT201400206A/es unknown
- 2014-09-29 CO CO14215143A patent/CO7091176A2/es unknown
- 2014-10-29 EC ECIEPI201425016A patent/ECSP14025016A/es unknown
-
2015
- 2015-02-05 HK HK15101259.7A patent/HK1200723A1/xx unknown
Also Published As
| Publication number | Publication date |
|---|---|
| CO7091176A2 (es) | 2014-10-21 |
| AU2013241752B2 (en) | 2016-07-07 |
| NZ628596A (en) | 2015-10-30 |
| BR112014023530A2 (pt) | 2017-07-18 |
| EA201491787A1 (ru) | 2015-01-30 |
| US20150111927A1 (en) | 2015-04-23 |
| WO2013144249A1 (en) | 2013-10-03 |
| EA028984B1 (ru) | 2018-01-31 |
| IN2014DN08970A (es) | 2015-05-22 |
| ECSP14025016A (es) | 2015-09-30 |
| CL2014002576A1 (es) | 2015-01-23 |
| ES2845560T3 (es) | 2021-07-27 |
| ZA201405938B (en) | 2015-11-25 |
| TW201345525A (zh) | 2013-11-16 |
| CN104271136A (zh) | 2015-01-07 |
| CA2866127A1 (en) | 2013-10-03 |
| EP2830621A1 (en) | 2015-02-04 |
| KR20140138771A (ko) | 2014-12-04 |
| US9795596B2 (en) | 2017-10-24 |
| IL234658B (en) | 2018-02-28 |
| SG10201608001RA (en) | 2016-11-29 |
| JP2015514080A (ja) | 2015-05-18 |
| HK1200723A1 (en) | 2015-08-14 |
| JP6224067B2 (ja) | 2017-11-01 |
| PH12014502168A1 (en) | 2014-12-10 |
| MX2014011682A (es) | 2015-01-22 |
| AU2013241752A1 (en) | 2014-09-25 |
| EP2830621B1 (en) | 2020-10-21 |
| SG11201405169SA (en) | 2014-10-30 |
| GT201400206A (es) | 2017-09-28 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CY1124307T1 (el) | Φαρμακευτικη συνθεση, μεθοδοι θεραπειας και χρησεις αυτων | |
| CY1121203T1 (el) | Θεραπευτικες χρησεις της εμπαγλιφλοζινης | |
| MX2021002406A (es) | Composiciones farmaceuticas que comprenden un inhibidor de il-4r para usarse en el tratamiento de la esofagitis eosinofilica. | |
| BR112018011272A2 (pt) | regimes de dosagem para 2-hidróxi-6-((2-(1-isopropil-1h-pirazol-5-il)piridin-3-il)metóxi)benzaldeído | |
| EA201691683A1 (ru) | Антитела против dll3 и конъюгаты антитело-лекарственное средство для применения при меланоме | |
| EA201692285A8 (ru) | Ингибиторы ezh2 для лечения лимфомы | |
| AR090544A1 (es) | Metodo para tratar selectivamente a un sujeto que tenga cancer | |
| EA201300810A1 (ru) | Противораковая терапия с использованием двойных ингибиторов киназ аврора/мек | |
| AR090903A1 (es) | Anticuerpos e inmunoconjugados anti-pmel17 | |
| UA115034C2 (uk) | Імунокон'югат для застосування в лікуванні раку або запального порушення | |
| BR112015020466A2 (pt) | inibidores de cdc7 | |
| BR112013029330A8 (pt) | uso de anticorpo imunoconjugado maytansinoide anti-cd19 para o tratamento de sintomas de doenças de célula-b | |
| RS54328B1 (en) | MULTIPLE TREATMENT OF LAKVINIMOD SCLEROSIS | |
| EA201501032A1 (ru) | Фармацевтическая композиция, способы лечения и ее применения | |
| ECSP13013060A (es) | Composiciones de nucleasa terapéuticas y métodos | |
| AR065033A1 (es) | Metodos para prevenir y tratar trastornos neurodegenerativos | |
| CR20130377A (es) | Métodos y productos de fármaco para tratar enfermedad de alzheimer | |
| MX2014005996A (es) | Anticuerpo anti - adrenomedulina (adm) o fragmento de anticuerpo anti - adm o un andamio no ig anti - adm para usarse en terapia. | |
| CR11510A (es) | Uso de un inhibidor de la gamma-secretasa para tratamiento del cancer | |
| CO7310528A2 (es) | Composición farmacéutica recubierta que contiene regorafenib | |
| RS52102B (en) | PIRPHENIDONE THERAPY Avoiding FLUVOXAMINE | |
| EA200900091A1 (ru) | Новые показания к применению прямых ингибиторов тромбина в лечении сердечно-сосудистых заболеваний | |
| CL2013001591A1 (es) | Compuestos derivados de triazolopiridina; inhibidores de pde10a; proceso de obtencion; composicion farmaceutica; y uso en el tratamiento o profilaxis de trastornos psicoticos, esquizofrenia, ansiedad, entre otras enfermedades. | |
| BR112016002401A8 (pt) | Métodos para reduzir as taxas de exacerbação de asma usando benralizumab | |
| AR093182A1 (es) | Metodo para tratar el sobrepeso o la obesidad |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FB | Suspension of granting procedure |